Atrophy detection for tissue occluded by implantable expansion device

By integrating sensors and controllers in implantable expansion devices, detecting fluid pressure and pumping time, the problem of early tissue atrophy detection is solved, and early clinical intervention and device life is achieved.

CN118922150APending Publication Date: 2024-11-08BOSTON SCIENTIFIC SCIMED INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380027902.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-03-13
Filing Date
2023-03-14
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

After the existing implantable expansion device occludes tissue for a long time, it is difficult to detect tissue atrophy early, resulting in reduced or lost treatment effect, and surgical correction or replacement of the device may be required.

Method used

A device including an expandable member, a sensor and a controller is designed to detect atrophy of the patient's body part based on these data to avoid surgical intervention by detecting the fluid pressure and the amount of fluid pumping time within the expandable member.

Benefits of technology

Early detection and monitoring of tissue atrophy is achieved, which can prevent or reverse atrophy, reduce the need for surgical procedures, and extend the service life of the device.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922150A_ABST
    Figure CN118922150A_ABST
Patent Text Reader

Abstract

A device includes a body implant configured to be implanted into a body of a patient. A body implant includes an expandable member, a sensor, and a controller. The expandable member is configured to be disposed within and apply pressure to a portion of a patient's body. A sensor is operatively coupled to the expandable member and configured to detect a fluid pressure within the expandable member. The controller is configured to receive pressure data from the sensor during a transition between the contracted configuration and the expanded configuration of the expandable member, and detect atrophy of the portion of the patient's body based on the received pressure data.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application is a continuation of and claims priority to U.S. non-provisional patent application No. 18 / 182,630, filed on March 13, 2023, entitled “ATROPHY DETECTION FOR TISSUE OCCLUDED BY IMPLANTABLE INFLATION DEVICES,” which claims priority to U.S. provisional patent application No. 63 / 269,433, filed on March 16, 2022, entitled “ATROPHY DETECTION FOR TISSUE OCCLUDED BY IMPLANTABLE INFLATION DEVICES,” the disclosure of which is incorporated herein by reference in its entirety.

[0003] This application also claims priority to U.S. Provisional Application No. 63 / 269,433, filed on March 16, 2022, the disclosure of which is incorporated herein by reference in its entirety. Technical Field

[0004] The present disclosure relates generally to body implants and, more particularly, to the detection of atrophy of tissue within a patient occluded by an expandable implantable device. Background Art

[0005] An implantable expansion device placed in a patient's body may include an expandable member configured to occlude the patient's tissue for therapeutic purposes. Such devices, such as an artificial urinary sphincter (AUS) device, can occlude a patient's tissue (such as the urethra) for a long period of time and continuously. Such occlusion may sometimes result in atrophy of the tissue surrounded and / or occluded by the expandable member tissue. In addition to the symptoms and complications that may be associated with such tissue atrophy, the therapeutic effect of the device may also be reduced or completely lost, which may result in the need for surgical intervention to correct or replace the implantable expansion device. Summary of the invention

[0006] In some aspects, the technology described herein relates to a device comprising: a body implant configured to be implanted into a patient's body, the body implant comprising an expandable member, a sensor, and a controller, the expandable member being configured to be disposed within a portion of the patient's body and to apply pressure to the portion of the patient's body, the sensor being operatively connected to the expandable member and configured to detect fluid pressure within the expandable member, and the controller being configured to receive pressure data from the sensor during a transition between a contracted configuration and an expanded configuration of the expandable member, and to detect collapse of the portion of the patient's body based on the received pressure data.

[0007] In some aspects, the technology described herein relates to a device in which an expandable member is configured to apply pressure to a portion of a patient's body when in an expanded configuration.

[0008] In some aspects, the technology described herein relates to a device wherein: a body implant includes a pump that is operably connected to an expandable member and is configured to pump fluid into the expandable member to transform the expandable member from a contracted structure to an expanded structure; and detection of shrinkage of a portion of a patient's body is based on the amount of time it takes the pump to transform the expandable member from a contracted structure to an expanded structure.

[0009] In some aspects, the technology described herein relates to an apparatus wherein detection of collapse of a portion of a patient's body is further based on a comparison of an amount of time taken by a pump to transition an expandable member from a collapsed configuration to an expanded configuration to a baseline expansion time.

[0010] In some aspects, the technology described herein relates to an apparatus wherein a baseline expansion time is determined while a body implant is implanted in a patient.

[0011] In some aspects, the technology described herein relates to a device wherein: a body implant includes a pump that is operably connected to an expandable member and is configured to pump fluid out of the expandable member to convert the expandable member from an expanded structure to a contracted structure; and detection of shrinkage of a portion of a patient's body is based on the amount of time it takes the pump to convert the expandable member from an expanded structure to a contracted structure.

[0012] In some aspects, the technology described herein relates to an apparatus wherein detection of collapse of a portion of a patient's body is further based on a comparison of an amount of time it takes a pump to transition an expandable member from an expanded configuration to a collapsed configuration to a baseline collapse time.

[0013] In some aspects, the technology described herein relates to an apparatus wherein a baseline contraction time is determined while a body implant is implanted in a patient.

[0014] In some aspects, the technology described herein relates to a device wherein: a body implant includes a pump that is operably connected to an expandable member and is configured to pump fluid into the expandable member to transform the expandable member from a contracted structure to an expanded structure; and detection of shrinkage of a part of the patient's body is based on the volume of fluid used to transform the expandable member from a contracted structure to an expanded structure.

[0015] In some aspects, the technology described herein relates to an apparatus in which a controller is configured to determine a volume of a fluid based on a flow rate of a pump.

[0016] In some aspects, the technology described herein relates to a device wherein detection of collapse of a portion of a patient's body is further based on comparison of a volume of fluid used to transition an expandable member from a contracted configuration to an expanded configuration with a baseline volume of fluid used to transition the expandable member from a contracted configuration to an expanded configuration, the baseline volume being determined when the body implant is implanted in the patient.

[0017] In some aspects, the technology described herein relates to a device wherein: a body implant includes a pump that is operably connected to an expandable member and is configured to pump fluid out of the expandable member to transform the expandable member from an expanded structure to a contracted structure; and detection of shrinkage of a part of the patient's body is based on the volume of fluid used to transform the expandable member from an expanded structure to a contracted structure.

[0018] In some aspects, the technology described herein relates to an apparatus in which a controller is configured to determine a volume of a fluid based on a flow rate of a pump.

[0019] In some aspects, the technology described herein relates to a device wherein detection of collapse of a portion of a patient's body is further based on comparison of a volume of fluid used to transition an expandable member from an expanded configuration to a contracted configuration with a baseline volume of fluid used to transition the expandable member from an expanded configuration to a contracted configuration, the baseline volume being determined when the body implant is implanted in the patient.

[0020] In some aspects, the technology described herein relates to a device wherein the expandable member is an expandable cuff.

[0021] In some aspects, the technology described herein relates to a device wherein the inflatable cuff is an artificial urinary sphincter.

[0022] In some aspects, the technology described herein relates to a device wherein: the portion of a patient's body is the patient's urethra; and pressure applied by an expandable member occludes the lumen of the urethra.

[0023] In some aspects, the technology described herein relates to a method comprising: converting an expandable member of a body implant implanted in a patient's body between a contracted structure and an expanded structure, the expandable member being configured to be disposed within a portion of the patient's body and to apply pressure to the portion of the patient's body; during the conversion, determining pressure data corresponding to a fluid pressure within the expandable member, and detecting shrinkage of the portion of the patient's body based on the pressure data.

[0024] In some aspects, the technology described herein relates to a method wherein: the transition is from a contracted structure to an expanded structure; and the detection of shrinkage of a portion of the patient's body is based on one of: the amount of time to transition the expandable member from the contracted structure to the expanded structure; and the volume of fluid used to transition the expandable member from the contracted structure to the expanded structure.

[0025] In some aspects, the technology described herein relates to a method wherein: the transition is from an expanded structure to a contracted structure; and detection of collapse of a portion of a patient's body is based on one of: the amount of time to transition an expandable member from an expanded structure to a contracted structure; and the volume of fluid used to transition the expandable member from an expanded structure to a contracted structure. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 is a schematic diagram of an implantable expansion device according to one aspect.

[0027] Figure 2A and Figure 2B is a schematic diagram of an implantable expansion device according to additional aspects.

[0028] Figure 3 is a graph showing a comparison of pressure data during inflation of an implantable device simulating tissue shrinkage according to one aspect.

[0029] Figure 4 is a diagram showing a method for using a curve after smoothing according to one aspect. Figure 3 Figure 2 shows a method for detecting tissue atrophy.

[0030] Figure 5 An example of an electronic pump assembly according to one aspect is shown. DETAILED DESCRIPTION

[0031] Detailed embodiments are disclosed herein. However, it should be understood that the disclosed embodiments are merely examples, which may be implemented in various forms. Therefore, the specific structural and functional details disclosed herein should not be interpreted as limiting, but merely as a basis for the claims, and as a representative basis for teaching those skilled in the art to adopt the embodiments in various ways in almost any appropriate detailed structure. In addition, the terms and phrases used herein are not intended to be limiting, but to provide an understandable description of the present disclosure.

[0032] As used herein, the terms "a" or "an" are defined as one or more than one. The term "another," as used herein, is defined as at least a second or more. The terms "including" and / or "having," as used herein, are defined as comprising (i.e., open ended conversions). The terms "coupled" or "removably coupled," as used herein, are defined as connected, although not necessarily directly and not necessarily mechanically.

[0033] Typically, embodiments relate to body implants. The term "patient" or "user" may be used hereinafter for a person who benefits from a medical device or method disclosed in the present disclosure. For example, a patient may be a person whose body is implanted with a medical device or a person who implements a method for operating a medical device disclosed in the present disclosure.

[0034] The implantable expansion devices (body implants) and related methods described herein can be used to detect atrophy of patient tissue that may be caused by such expansion devices when used for therapeutic purposes. Such tissue atrophy may be the result of occlusive pressure exerted on the tissue by the expandable member of the body implant. For example, higher occlusive pressures may lead to an increased risk of such tissue atrophy. Because current embodiments of body implant devices do not have the ability to detect and identify tissue atrophy early, the occurrence of such atrophy is manifested through other external symptoms, such as pain, tissue trauma and / or loss of therapeutic effect. Once such external symptoms occur, the patient may require surgery to eliminate the effects of tissue atrophy, which may be irreversible.

[0035] The body implants and related methods described herein can provide early detection of the occurrence of tissue atrophy, which can facilitate early clinical intervention, such as corrective therapy, to prevent further atrophy, or potentially reverse detected tissue atrophy. For example, the devices described herein can monitor and adjust the occlusion pressure of the expandable member. In such embodiments, such monitoring and adjustment of patient treatment can also be used to detect and prevent potential urethral atrophy without the need for surgical intervention, or without the need for such atrophy to be manifested by external symptoms. In some embodiments, the expandable member can be an expandable cuff used as an artificial urinary sphincter (AUS) to occlude the patient's urethra for the treatment of urinary incontinence.

[0036] Figure 1is a schematic diagram of an implantable expansion device 100 or body implant according to one aspect. Device 100 , as well as other example devices described herein, are configured to detect potential collapse of patient tissue caused by occlusive pressure applied by an expandable member of device 100 .

[0037] Device 100 includes a fluid reservoir 110, a pump assembly 130, and an expandable member 150. In some embodiments, fluid reservoir 110 may be a pressure regulating balloon (PRB). Figure 1 As shown, the fluid reservoir 110 is operably or fluidically coupled to the pump assembly 130 via a connecting member 180. The connecting member 180 can be a tubular member, such as a kink-resistant tubing (KRT). In other embodiments, the fluid reservoir 110 is operably or fluidically coupled to the pump assembly 130 via a different mechanism. Similarly, the expandable member 150 is operably or fluidically coupled to the pump assembly 130 via a connecting member 190. The connecting member 190 can be a tubular member, such as a kink-resistant tubing (KRT). In other embodiments, the expandable member 150 is operably or fluidically coupled to the pump assembly 130 via a different mechanism.

[0038] The implantable expansion device 100 can be configured to be implanted into a patient or user. For example, in some embodiments, the implantable expansion device 100 is an AUS. In such embodiments, the expandable member 150 can be implanted to surround the urethra of the patient or user. The fluid reservoir 110 can be implanted in the abdomen or pelvis of the user (e.g., the fluid reservoir 110 can be implanted in the lower portion of the user's abdomen or the upper portion of the user's pelvis), and the pump assembly 130 and the associated control module 170 can be implanted in a portion of the user's body (such as the user's abdomen). In other embodiments, the implantable expansion device 100 is implanted in a different portion of the patient's body and / or for a different purpose.

[0039] Pump assembly 130 may include one pump or more than one pump configured to pump fluid from reservoir 110 to expandable member 150 during an inflation cycle. In some examples, one or more pumps may be mechanically and / or programmatically controlled by control module 170. In some embodiments, fluid reservoir 110 may be a PRB and pump assembly 130 may include a valve that regulates the flow of inflation fluid from fluid reservoir 110 to expandable member 150.

[0040] The expandable member 150 is capable of expanding when a fluid is injected into the cavity of the expandable member 150. In some embodiments, the expandable member 150 may include a cylindrical cuff or AUS that can be implanted in a patient around the connection between the patient's bladder and ureters (such as the patient's urethra) as a treatment for urinary incontinence. For example, the patient can expand and contract the expandable member 150 (AUS) to control the flow of urine. That is, when the expandable member 150 is expanded, the urethra can be occluded and the flow of urine is inhibited, while contracting the expandable member 150 allows urine to flow and allows the patient to empty their bladder by controlling the expandable member 150. In an embodiment of the AUS, the cylindrical cuff may include a rigid outer backing so that the cuff expands only inward when expanded.

[0041] The fluid reservoir 110 can include a container having an internal cavity or chamber that is configured to hold or contain a fluid for inflating the expandable member 150. The volume capacity of the fluid reservoir 110 can vary. In some examples, the volume capacity of the fluid reservoir 110 can be 3 to 150 cubic centimeters. In some examples, the fluid reservoir 110 is made of the same material as the expandable member 150 (e.g., silicone). In other examples, the fluid reservoir 110 is made of a different material than the expandable member 150. In some examples, the fluid reservoir 110 can be sized to hold a larger volume of fluid than the expandable member 150.

[0042] The device 100 also includes a pressure sensor 151, which can be disposed in the fluid path of the connecting member 190, or can be otherwise operably coupled to the expandable member 150 or the connecting member 190 to sense the fluid pressure in the expandable member 150. Figure 1 As shown, in this example, the pressure sensor 151 is operably connected to the control module 170, and the control module 170 can be configured to receive pressure data from the pressure sensor 151 for implementing the methods described herein. That is, the control module 170 can be configured to receive and monitor the occlusion pressure applied by the expandable member 150, determine the amount of time it takes the pump assembly 130 to expand the expandable member 150, and / or determine the volume of fluid used to achieve the target occlusion pressure. The control module 170 can also be configured to detect potential tissue atrophy, such as tissue atrophy of the patient's urethra, based on a comparison of the expansion time and / or expansion volume with a baseline value. In some embodiments, the baseline value can be determined when the implant is implanted in the patient, can be a value determined by the clinician when revising the treatment plan, etc.

[0043] In some embodiments, the control module 170 can be configured to receive and monitor the occlusion pressure applied by the expandable member 150 during the transition from the expanded configuration to the collapsed configuration, determine the amount of time it takes the pump assembly 130 to collapse the expandable member 150, and / or determine the volume of fluid used to achieve the target collapsed pressure. The control module 170 can also be configured to detect potential tissue atrophy, such as tissue atrophy of the patient's urethra, based on a comparison of the collapsed time and / or collapsed volume with a baseline value. In some embodiments, the baseline value can be determined when the implant is implanted in the patient, can be a value determined by a clinician when revising a treatment regimen, etc.

[0044] exist Figure 1 In the illustrated embodiment, the control module 170 is also operably coupled to the pump assembly 130. In some embodiments, the pump assembly 130, the control module 170, and / or the pressure sensor 151 can be integrated into a single component or module and included in a common housing that can be implanted in a patient. In some embodiments, the control module 170 is configured to activate and deactivate one or more pumps of the pump assembly 130, such as in response to an external controller 177, which can communicate with the control module 170 via a wireless link 178, which can be a two-way wireless link. Thus, the control module 170 can be configured to activate or deactivate one or more pumps upon request of a patient or user, such as in response to a signal from the external controller 177, so as to control the expansion pressure or state (expanded state or contracted state) of the expandable member 150, such as expanding the expandable member 150 to a target occlusion pressure. In some embodiments, the external controller 177 can be implemented using a smartphone application.

[0045] Figure 2A and Figure 2B Schematic diagrams of implantable expansion devices, such as device 200a and device 200b, respectively, according to additional aspects. Devices 200a and 200b are provided as examples and for illustrative purposes as embodiments of body implants in which the methods described herein may be implemented.

[0046] refer to Figure 2A, implantable expansion device 200a includes pressure regulating balloon 210a, pump assembly 230a, expandable AUS250a and pressure sensor 251a, which can be fluidly connected to each other as shown in the figure. In this example, pressure regulating balloon 210a acts as a fluid reservoir of device 200a, and provides fluid pressure to expand expandable AUS250a, for example, to occlude the patient's urethra. Pump assembly 230a includes pump 232a and valve 234a. When expandable AUS250a is expanded (for example, with an expansion fluid such as saline), pump 232a can be used to shrink expandable AUS250a so that patients can empty their bladders. After patients empty their bladders, patients can indicate (such as using an external controller) that expandable AUS250a should be expanded again.

[0047] In the device 210a, the pressure sensor 251a can be configured to measure the fluid pressure in the inflatable AUS 250a to ensure that the target occlusion pressure is applied when the inflatable AUS 250a is inflated. For example, the pressure sensor 251a can be used as a feedback mechanism controlled by the control module. The control module can then control the valve 234a and the pump 232a, for example, to maintain the target occlusion pressure in the inflatable AUS 250a, or control the deflation of the inflatable AUS 250a when requested by the patient.

[0048] refer to Figure 2B , the device 200b includes a non-pressurized fluid reservoir 210b, a pump assembly 230b, an expandable AUS 250b, and a pressure sensor 251b, which can be fluidly coupled to each other as shown. Figure 2A Compared to the device 210a of FIG. 200a, the pump assembly 230b includes a pump 232b for deflating 205b and a pump 234b for inflating the inflatable AUS 250b. Similar to the device 200a, the pressure sensor 251b of the inflatable AUS 250b can be configured to measure the fluid pressure in the inflatable AUS 250b to ensure that the target occlusion pressure is applied. For example, the pressure sensor 251b can be used as a feedback mechanism controlled by a control module, which can control the pumps 232b and 234b to maintain the target occlusion pressure in the inflatable AUS 250b, or control the deflating of the inflatable AUS 250b.

[0049] Figure 3 is a graph showing pressure data during inflation of an implantable device simulating tissue shrinkage compared to pre-shrinkage (baseline) according to one aspect. Figure 3The data shown shows the change in fluid pressure (cmH2O) over time within a 5 centimeter (cm) inner diameter AUS as it is inflated (e.g., using a pump or PRB to inject inflation fluid into the AUS). In this example, trace 310 shows occlusion of a 5 cm urethra (e.g., occlusion of the lumen of the urethra), which can represent a baseline data urethral diameter. Also in Figure 3 , trace 320 shows data for a 4 cm urethral occlusion, which may represent shrinkage from a 5 cm baseline. Figure 3 The initial negative pressure shown in the two sets of data in is due to the deflation pump evacuating the AUS, causing a vacuum to be created in the AUS due to the removal of the inflation fluid.

[0050] Also like Figure 3 As shown in each set of data in , when inflation begins, as inflation fluid is transferred or pumped into the AUS (e.g., from a corresponding fluid reservoir via a pump or due to a pressure difference in the PRB), the fluid pressure in the AUS quickly rises to a first plateau (P1 of trace 310 and P2 of trace 320). These plateaus of P1 and P2 are at relatively low fluid pressures compared to the target occlusion pressure. That is, the corresponding fluid pressure during the P1 and P2 plateaus is due to the AUS being filled with inflation fluid, but pressure has not yet been applied to the corresponding urethra. Once the AUS is filled enough to begin applying pressure to the corresponding urethra, as shown in both sets of data, the pressure within the AUS begins to rise again until a second plateau is reached, wherein the second plateau corresponds to the final desired occlusion pressure, or the target occlusion pressure applied to the urethra.

[0051] for Figure 3 For each trace in FIG, the respective amount of time spent in the first plateaus P1 and P2 corresponds to the amount of time it takes for the AUS to fill to the point where it begins to apply pressure to the urethra, e.g., after an initial period of transition from an internal negative fluid pressure (vacuum) to a positive fluid pressure as the AUS begins to fill with inflation fluid.

[0052] By comparison Figure 3 It can be seen from the data of P1 and P2 that the larger the gap between the unexpanded inner diameter of the AUS and the urethra (no gap in trace 310, 1 cm diameter difference in trace 320), the longer the time spent in the corresponding plateau region. Therefore, the controller is configured to measure the corresponding amount of time for P1 and P2 (such as Figure 4), and determining the difference between these times can be used as a method to indicate whether any changes (such as tissue atrophy) have occurred over time and with the use of the AUS. For example, if at the time of implantation (baseline), the time spent in the plateau region (e.g., P1) for the AUS is 15 seconds, and 3 months after implantation of the AUS, the time spent in the plateau region (e.g., P1) for the AUS is a constant 25 seconds, this difference may indicate that the occluded tissue (e.g., the patient's urethra) has atrophied.

[0053] In some body implant embodiments, reference Figure 3 For example, the amount of atrophy can be determined based on the difference between the baseline volume of fluid used to achieve the target occlusion pressure in P1 and the volume of fluid used to achieve the target occlusion pressure in P2. This approach is effective for determining the amount of occlusion based on such a volume difference because the AUS cuff is typically implemented as a cylinder with a known outer diameter and includes a rigid backing so that the volume of fluid used to inflate the AUS can be used to determine its inner diameter. For example, due to the limitation of the rigid backing to outward expansion, the inflatable portion of the AUS can only expand inwardly. Therefore, the difference between two such inner diameters (e.g., baseline and post-atrophy detection) will correspond to the amount of urethral atrophy, which can be determined by a simple difference between the corresponding volume calculations.

[0054] exist Figure 3 In the data of FIG. 1 , for example, during P1 and P2, the changes observed in the fluid pressure data are due, at least in part, to the pillows formed as the AUS expands and the interaction between the AUS and the surrounding urethral tissue, for example, as the AUS engages and then releases and / or moves over the urethra until full circumferential engagement occurs. At this point, the corresponding fluid pressure in the AUS rises until a final or target occlusion pressure is reached. Although Figure 3 The data in has noise and environmental artifacts, but the data shows that the plateau of P2 is longer than the plateau of P1, which may indicate atrophy, for example, a 4 cm atrophic urethra diameter compared to a 5 cm baseline urethra diameter. In the embodiments described herein, the control module can be configured to process the pressure data captured by the pressure sensor (e.g. Figure 3 curve smoothing is applied to the pressure data, where such smoothed or curve-fitted pressure data are Figure 4 The smoothed data can then be used to identify potential occurrences of tissue atrophy.

[0055] As mentioned above, Figure 4 is a diagram showing a method for using a curve after smoothing according to one aspect. Figure 3 The trace 400 and the trace 420 are respectively related to Figure 3Trace 310 and trace 320 correspond to curve fitting or smoothing of pressure data. Figure 4 , for trace 410, line 415a and line 415b are fitted lines of the slope of the fluid pressure within the AUS relative to time before and after the initial plateau region P1, respectively. Similarly, for trace 420, line 425a and line 425b are fitted lines of the slope of the fluid pressure within the AUS relative to time before and after the initial plateau region P2, respectively. Line 430 is a benchmark for approximating or representing the P1 plateau and the P2 plateau, and is also used as an intersection with the inclined dotted line. The distance between these two intersections, shown as P1a and P2a, can be used to compare how the corresponding tissue (e.g., the patient's urethra) responds to the applied therapeutic occlusion pressure over time, and to determine whether the tissue is undergoing atrophy.

[0056] As mentioned above, Figure 4 The times P1a and P2a in correspond to the corresponding times spent in the first plateau region (e.g., the low pressure state when the AUS is filled to the point of full contact with the surrounding tissue). In order to determine whether atrophy has occurred, a threshold change value can be used. For example, a 15% increase in the time spent in the first plateau region can be used. In this embodiment, an increase of less than 15% in P2a over P1a can be considered to indicate that atrophy has not occurred, while an increase of 15% or more in P2a over P1a can be considered to indicate that atrophy has occurred. In an exemplary embodiment, a control module corresponding to a body implant can be configured to notify a patient or physician of an indication of potential atrophy. Such notification can be provided in various ways, such as by remotely communicating with a physician through a data network accessible to a controller, for example, during a physician's inquiry into the device. Alternatively, as another example, the control module can notify the patient to contact their physician (e.g., via an external controller for a body implant). In addition, even if the atrophy indication threshold is not reached, trends can be observed and used to predict potential future problems.

[0057] Obviously, the amount of time spent in the above-mentioned plateau region depends on the speed at which the AUS is filled. Figure 4 The initial pressure slopes shown in (lines 415a and 425a) can be used to determine a corresponding fill rate because the AUS needs to move very little fluid from the vacuum state to the first plateau. By determining a corresponding fill rate for the AUS, for example, when comparing the corresponding amounts of time spent in the plateau region (e.g., P1a and P2a), any corresponding atrophy determination can be adjusted for this difference in fill rate. This adjustment can be important when using an electronic pump because no two pumps will pump at exactly the same rate. In addition, the efficiency or performance of a given pump may change over time and with use.

[0058] In some embodiments, the determination or detection of collapse can be based on transitioning an expandable member (such as those described herein) from an expanded configuration to a collapsed configuration. In such embodiments, the pressure data used can be substantially similar to Figure 3 and Figure 4 The pressure data shown are the opposite of the pressure data.

[0059] Figure 5 An example of a portion of an electronic pump assembly 530 according to one aspect is shown. The electronic pump assembly 530 or a portion thereof may be Figure 1 The pump assembly 130 and / or Figure 2A and Figure 2B Examples of corresponding pump assemblies 230a and 230b of the device and can include any of the details discussed with reference to the expandable devices or body implants described herein.

[0060] The electronic pump assembly 530 is configured to transfer fluid between the fluid reservoir 510 and the expandable member 550 (e.g., an expandable AUS cuff). The electronic pump assembly 530 can transfer fluid between the fluid reservoir 510 and the expandable member 550 via one or more pumps without requiring the user to manually operate the pump (e.g., squeeze and release the pump ball).

[0061] For example, the electronic pump assembly 530 includes a pump 520-1 disposed in a fluid channel 527 (e.g., a filling channel), and an active valve 518 disposed in a fluid channel 524 (e.g., an emptying channel). The pump 520-1 may be an electromagnetic pump or a piezoelectric pump. The pump 520-1 may include a passive check valve 523 and a passive check valve 525. The fluid channel 527 may be a fluid branch that is separate (and parallel) from the fluid channel 524. The fluid channel 527 is a channel that transfers fluid from the fluid reservoir 510 to the expandable member 550. The fluid channel 524 is a channel that transfers fluid from the expandable member 550 to the fluid reservoir 510. The pump 520-1 is disposed in parallel with the active valve 518.

[0062] In some examples, the electronic pump assembly 530 may include an active valve 519 in series with the pump 520-1 (e.g., the pump 520-1 and the active valve 519 are disposed in the fluid channel 527). In some examples, the electronic pump assembly 530 may include a pump 520-2 in series with the active valve 518 (e.g., the pump 520-2 and the active valve 518 are disposed in the fluid channel 524). The pump 520-2 may be an electromagnetic pump or a piezoelectric pump. The pump 520-2 may include a passive check valve 523 and a passive check valve 525. In some examples, the electronic pump assembly 530 includes an active valve 548 that is fluidly connected to the fluid reservoir 510. The active valve 548 may be in series with the active valve 518 (and the pump 520-2) or the pump 520-1 (and the active valve 519). In some examples, the electronic pump assembly 530 includes an active valve 552 that is fluidly connected to the expandable member 550. Active valve 552 may be connected in series with active valve 519 (and pump 520 - 1 ) or pump 520 - 2 (and active valve 518 ).

[0063] Active valve 548, pump 520-1, active valve 518, active valve 552, active valve 518, and pump 520-2 may be controlled by a controller and / or driver (e.g., Figure 1 The control module 170, and / or in combination Figure 2A and Figure 2B The pump 520-1 and the pump 520-2 may be unidirectional or bidirectional. With respect to the fluid channel 527, in some examples, the pump 520-1 and the active valve 519 may swap positions (e.g., the active valve 519 is connected in series between the active valve 548 and the pump 520-1). With respect to the fluid channel 524, in some examples, the active valve 518 and the pump 520-2 may swap positions (e.g., where the pump 520-1 is connected in series with the active valve 518 and the active valve 548 and is located between the active valve 518 and the active valve 548).

[0064] In some examples, one or more additional active valves and / or one or more additional pumps are disposed in series within fluid channel 527. In some examples, one or more additional active valves and / or one or more additional pumps are disposed in series within fluid channel 524. In some examples, electronic pump assembly 530 may include one or more additional (and parallel) fluid channels, wherein each additional (and parallel) fluid channel may include one or more active valves and one or more pumps.

[0065] In some examples, such as those described herein, electronic pump assembly 530 may include pressure sensor 531 and pressure sensor 532. Pressure sensor 531 and pressure sensor 532 are connected to a controller (e.g., Figure 1 The control module 170, and / or in combination Figure 2A and Figure 2B A control module implemented in the device), wherein the controller receives measured pressures from pressure sensor 531 and pressure sensor 532, respectively, and can use those pressure readings and related filling rate information to detect tissue atrophy of the patient, as described herein.

[0066] For example, pressure sensor 531 is configured to measure the fluid pressure in expandable member 550. The controller can receive the measured pressure from pressure sensor 531 and, in response, automatically control the active valve and / or pump to adjust the pressure, and / or provide a notification about the detection of potential tissue atrophy. In some examples, pressure sensor 532 is configured to measure the pressure in fluid reservoir 510. In some examples, pressure sensor 532 can detect intra-abdominal pressure (which may increase during activities such as exercise), and the controller can control the active valve and pump to minimize or prevent accidental expansion. In some examples, electronic pump assembly 530 may include one or more pressure sensors at other locations within electronic pump assembly 530. For example, the pressure sensor can be disposed between active valve 548 and pump 520-1. In some examples, the pressure sensor can be disposed between pump 520-1 and active valve 519. In some examples, the pressure sensor can be disposed between active valve 548 and active valve 518. In some examples, the pressure sensor can be disposed between active valve 518 and pump 520-2. In some examples, a pressure sensor may be placed between expandable member 550 and active valve 552 .

[0067] While certain features of the described embodiments have been illustrated as described herein, many modifications, substitutions, changes and equivalents will now occur to those skilled in the art. It is therefore to be understood that the appended claims are intended to cover all such modifications and changes that fall within the scope of the embodiments.

Claims

1. A device comprising: a body implant configured to be implanted into a patient, the body implant comprising an expandable member, a sensor, and a controller, The expandable member is configured to be disposed within a portion of a patient's body and to apply pressure to the portion of the patient's body, The sensor is operatively coupled to the expandable member and is configured to detect fluid pressure within the expandable member, and The controller is configured to receive pressure data from the sensor during transition between the collapsed configuration and the expanded configuration of the expandable member and detect collapse of the portion of the patient's body based on the received pressure data.

2. The device according to claim 1, wherein: The expandable member is configured to apply pressure to the portion of the patient's body when in the expanded configuration.

3. The apparatus according to any one of the preceding claims, wherein: The body implant includes a pump operatively coupled to the expandable member and configured to pump a fluid into the expandable member to transition the expandable member from a collapsed configuration to an expanded configuration; and Detection of collapse of the portion of the patient's body is based on an amount of time it takes the pump to transition the expandable member from the collapsed configuration to the expanded configuration.

4. The device according to claim 3, wherein: Detection of collapse of the portion of the patient's body is further based on a comparison of an amount of time taken by the pump to transition the expandable member from the collapsed configuration to the expanded configuration to a baseline expansion time.

5. The device according to claim 4, wherein: The baseline expansion time is determined when the body implant is implanted in a patient.

6. Apparatus according to any one of the preceding claims, wherein: The body implant includes a pump operatively coupled to the expandable member and configured to pump fluid out of the expandable member to transition the expandable member from an expanded configuration to a collapsed configuration; and Detection of collapse of the portion of the patient's body is based on an amount of time it takes the pump to transition the expandable member from the expanded configuration to the collapsed configuration.

7. The device according to claim 6, wherein: Detection of collapse of the portion of the patient's body is further based on a comparison of an amount of time taken by the pump to transition the expandable member from an expanded configuration to a collapsed configuration to a baseline collapse time.

8. The device according to claim 7, wherein: The baseline contraction time is determined when the body implant is implanted in a patient.

9. The apparatus according to any one of claims 1 or 2, wherein: The body implant includes a pump operatively coupled to the expandable member and configured to pump a fluid into the expandable member to transition the expandable member from a collapsed configuration to an expanded configuration; and The detection of collapse of the portion of the patient's body is based on a volume of fluid used to transition the expandable member from the collapsed configuration to the expanded configuration, The controller is configured to determine a volume of fluid based on a flow rate of the pump.

10. The device according to claim 9, wherein: Detection of atrophy of the portion of the patient's body is further based on a comparison of the volume of fluid used to transition the expandable member from a contracted configuration to an expanded configuration with a baseline volume of fluid used to transition the expandable member from a contracted configuration to an expanded configuration, the baseline volume being determined when the body implant is implanted in the patient.

11. The apparatus according to any one of claims 9 or 10, wherein: The body implant includes a pump operatively coupled to the expandable member and configured to pump fluid out of the expandable member to transition the expandable member from an expanded configuration to a collapsed configuration; and The detection of collapse of the portion of the patient's body is based on a volume of fluid used to transition the expandable member from the expanded configuration to the collapsed configuration, The controller is configured to determine a volume of fluid based on a flow rate of the pump.

12. The device according to claim 11, wherein Detection of atrophy of the portion of the patient's body is further based on comparison of the volume of fluid used to transition the expandable member from an expanded configuration to a contracted configuration with a baseline volume of fluid used to transition the expandable member from an expanded configuration to a contracted configuration, the baseline volume being determined when the body implant is implanted in the patient.

13. Apparatus according to any one of the preceding claims, wherein: The expandable member is an expandable cuff.

14. The device according to claim 15, wherein: The inflatable cuff is an artificial urinary sphincter.

15. Apparatus according to any one of the preceding claims, wherein: The part of the patient's body is the patient's urethra; and The pressure applied by the expandable member occludes the lumen of the urethra.

16. A device comprising: a body implant configured to be implanted in a patient, the body implant comprising an expandable member, a sensor, and a controller, The expandable member is configured to be disposed within a portion of a patient's body and to apply pressure to the portion of the patient's body, The sensor is operatively coupled to the expandable member and is configured to detect fluid pressure within the expandable member, and The controller is configured to receive pressure data from the sensor during a transition between the collapsed configuration and the expanded configuration of the expandable member and detect collapse of the portion of the patient's body based on the received pressure data.

17. The device according to claim 16, wherein: The expandable member is configured to apply pressure to the portion of the patient's body when in the expanded configuration.

18. The apparatus of claim 16, wherein: The body implant includes a pump operatively coupled to the expandable member and configured to pump a fluid into the expandable member to transition the expandable member from a collapsed configuration to an expanded configuration; and Detection of collapse of the portion of the patient's body is based on an amount of time it takes the pump to transition the expandable member from the collapsed configuration to the expanded configuration.

19. The apparatus according to claim 18, wherein: Detection of collapse of the portion of the patient's body is further based on a comparison of an amount of time taken by the pump to transition the expandable member from the collapsed configuration to the expanded configuration to a baseline expansion time.

20. The apparatus of claim 19, wherein: The baseline expansion time is determined when the body implant is implanted in a patient.

21. The apparatus of claim 16, wherein: The body implant includes a pump operatively coupled to the expandable member and configured to pump fluid out of the expandable member to transition the expandable member from an expanded configuration to a collapsed configuration; and Detection of collapse of the portion of the patient's body is based on an amount of time it takes the pump to transition the expandable member from the expanded configuration to the collapsed configuration.

22. The apparatus according to claim 21, wherein Detection of collapse of the portion of the patient's body is further based on a comparison of an amount of time taken by the pump to transition the expandable member from an expanded configuration to a collapsed configuration to a baseline collapse time.

23. The apparatus of claim 22, wherein: The baseline contraction time is determined when the body implant is implanted in a patient.

24. The apparatus of claim 16, wherein: The body implant includes a pump operatively coupled to the expandable member and configured to pump a fluid into the expandable member to transition the expandable member from a collapsed configuration to an expanded configuration; and Detection of collapse of the portion of the patient's body is based on the volume of fluid used to transition the expandable member from the collapsed configuration to the expanded configuration.

25. The apparatus of claim 24, wherein: The controller is configured to determine a volume of fluid based on a flow rate of the pump.

26. The apparatus of claim 25, wherein: Detection of atrophy of the portion of the patient's body is further based on a comparison of the volume of fluid used to transition the expandable member from a contracted configuration to an expanded configuration with a baseline volume of fluid used to transition the expandable member from a contracted configuration to an expanded configuration, the baseline volume being determined when the body implant is implanted in the patient.

27. The apparatus of claim 16, wherein: The body implant includes a pump operatively coupled to the expandable member and configured to pump fluid out of the expandable member to transition the expandable member from an expanded configuration to a collapsed configuration; and Detection of collapse of the portion of the patient's body is based on the volume of fluid used to transition the expandable member from the expanded configuration to the collapsed configuration.

28. The apparatus of claim 27, wherein: The controller is configured to determine a volume of fluid based on a flow rate of the pump.

29. The apparatus of claim 28, wherein: Detection of atrophy of the portion of the patient's body is further based on comparison of the volume of fluid used to transition the expandable member from an expanded configuration to a contracted configuration with a baseline volume of fluid used to transition the expandable member from an expanded configuration to a contracted configuration, the baseline volume being determined when the body implant is implanted in the patient.

30. The apparatus of claim 16, wherein: The expandable member is an expandable cuff.

31. The apparatus of claim 30, wherein: The inflatable cuff is an artificial urinary sphincter.

32. The apparatus of claim 16, wherein: The part of the patient's body is the patient's urethra; and The pressure applied by the expandable member occludes the lumen of the urethra.

33. A method comprising: transitioning an expandable member of a body implant implanted in a patient between a collapsed configuration and an expanded configuration, the expandable member being configured to be disposed within and apply pressure to a portion of the patient's body; During the transition, determining pressure data corresponding to the fluid pressure within the expandable member, and Shrinkage of the portion of the patient's body is detected based on the pressure data.

34. The method of claim 33, wherein: The transition is from a collapsed configuration to an expanded configuration; and Detection of atrophy of the portion of the patient's body is based on one of: an amount of time to transition the expandable member from a collapsed configuration to an expanded configuration; and The volume of fluid used to transition the expandable member from the collapsed configuration to the expanded configuration.

35. The method of claim 33, wherein: The transition is from an expanded configuration to a collapsed configuration; and Detection of atrophy of the portion of the patient's body is based on one of: an amount of time to transition the expandable member from an expanded configuration to a collapsed configuration; and The volume of fluid used to transition the expandable member from an expanded configuration to a collapsed configuration.